Anti Mullerian hormone (AMH) is gaining place as the most accurate biomarker reflecting ovarian response to gonadotropins stimulation in Assisted Reproductive Technology. We evaluated its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. \nMethodology: This retrospective analysis compiles the data of 166 infertile females, receiving IVF with ICSI treatment from June 2014 to March 2015. Serum samples taken on days 3 were assessed for Follicle Stimulating hormone (FSH), Luteinizing hormone, Estadiol and AMH. Antral follicle count was assessed on transvaginal ultrasound. Outcomes were measured as good (oocyte count of 5 to 19) and bad responders (less than 5 oocytes). \nResults: ROC analysis revealed higher discriminatory power of AMH (AUROC; 0.771; p < 0.05) in comparison to FSH (AUROC; 0.692; p < 0.05) and AFC (AUROC; 0.690; p < 0.01) in discriminating the responder groups. AMH reported stronger association versus FSH and AFC (odds ratio of 15.06, 4.12 and 0.81 respectively). Subgroup analysis reported 68.6 % risk of bad response in patients with AMH levels of less than 1.37ng/ml. This association was observed more significant in young infertile patients <35 year of age (r=0.245; p=0.012) versus older population >35 year (r=0.169; p>0.05).\nConclusion: Our study confirms that serum AMH correlates well with oocytes retrieval, particularly in infertile population younger than 35 years. We suggest AMH evaluation as a baseline assessment of infertile females that are falsely advised to postpone interventions based on their age and normal FSH levels.